APLM Apollomics Inc.

Nasdaq N/A


$ 35.40 $ 4.67 (14.6 %)    

Friday, 17-Oct-2025 19:12:42 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 36.65
$ 32.00
$ 33.50 x 150
$ 39.90 x 200
$ 32.00 - $ 40.02
$ 3.66 - $ 42.12
142,968
na
40.44M
$ 0.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nasdaq-cancels-delisting-hearing-for-apollomics-confirms-compliance-with-continued-listing-standards

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharma...

Core News & Articles

The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:AP...

 apollomics-fy24-eps-5280-up-from-23199-yoy

Apollomics (NASDAQ:APLM) reported quarterly losses of $(52.80) per share. This is a 77.24 percent increase over losses of $(231...

 apollomics-and-launxp-announce-development-and-commercialization-agreement-for-vebreltinib-apollomics-to-receive-upfront-payments-of-10m-and-is-eligible-for-pre-commercial-milestones-up-to-50m-and-royalties-on-net-product-sales

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION